Morphic Therapeutic announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc. (Janssen). The collaboration expansion involves the initiation of work on a third integrin target, with the collaboration scope to include activating antibodies against this new target. The agreement was facilitated by Johnson & Johnson Innovation. Under the terms of the original collaboration agreement, Morphic will receive a milestone payment for initiating work on the third target. As part of the expansion any new product candidates will be subject to milestones and royalties.